Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

By White W.B.   Faich G.   Borer J.S.   Makuch R.W.  

ACC Current Journal Review, Vol. 12, Iss. 6, 2003-11 ,pp. : 14-15

Elsevier

Access to resources Recommend Favorite

Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 23, Iss. 1, 2006-10 ,pp. : 8-21

Karger

Access to resources Recommend Favorite

Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan

By  

Digestion, Vol. 83, Iss. 1-2, 2010-11 ,pp. : 108-123

Karger

Access to resources Recommend Favorite

Cardiovascular Safety of Lubeluzole (Prosynap^®) in Patients with Ischemic Stroke

By  

Cerebrovascular Diseases, Vol. 8, Iss. 5, 1998-08 ,pp. : 247-254

Karger

Access to resources Recommend Favorite

Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients

By Van de Maele Boudewijn   Fabbri Leonardo M.   Martin Carmen   Horton Rachael   Dolker Michael   Overend Tim  

COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 7, Iss. 6, 2010-12 ,pp. : 418-427

Informa Healthcare

Access to resources Recommend Favorite